Adenosquamous Carcinoma of Extrahepatic Bile Duct: A Case Report by Lim, Sin Hyung et al.
The  Korean  Journal  of  Internal  Medicine  :  22:206-210,  2007
Adenosquamous Carcinoma of Extrahepatic Bile Duct: 
A Case Report
Sin Hyung Lim, M.D., Hyeon Woong Yang, M.D., Anna Kim, M.D., 
Sang Woo Cha, M.D., Sung Hee Jung, M.D., 
Hoon Go, M.D. and Woong Chul Lee, M.D.
Department  of  Internal  Medicine,  Eulji  University  School  of  Medicine,  Daejeon,  Korea
Most  malignant  tumors  originating  from  the  biliary  tract  are  adenocarcinomas,  and  adenosqamous  carcinoma  of 
Klatskin's  tumor  is  a  very  rare  finding.  An  83-yr-old  man  was  admitted  to  our  hospital  because  of  jaundice.  The 
abdominal  computed  tomography  and  magnetic  resonance  cholangiopancreatography  revealed  wall  thickening  and 
luminal  stenosis  of  both  the  intrahepatic  duct  confluent  portion  and  the  common  hepatic  duct.  These  findings  were 
compatible  with  Klatskin's  tumor,  Bismuth  type  III.  Considering  the  patient's  old  age,  palliative  combined  modality 
therapy  was  performed.  After  percutaneous  transhepatic  biliary  drainage,  biopsy  was  performed  via  percutaneous 
transhepatic  cholangioscopy.  The  histopathologic  findings  showed  adenosquamous  carcinoma.  External  radiotherapy 
and  intraluminal  brachytherapy  through  the  endobiliary  Y-type  stent  were  then  done.  Nine  months  after  the 
radiotherapy,  the  laboratory  findings  and  the  abdominal  computed  tomography  revealed  biliary  obstruction  and 
progressive  hepatic  metastasis.  The  combined  modality  therapy  of  external  radiotherapy,  intraluminal  brachytherapy  and 
stenting  assisted  him  to  live  a  normal  life  until  he  finally  experienced  biliary  obstruction.
Key  Words  :  Adenosquamous  carcinoma,  Klatskin's  tumor,  Brachytherapy
∙Received  :  October  9,  2006
∙Accepted  :  January  30,  2007
∙Correspondence to : Hyeon  Woong  Yang,  M.D.,  Professor,  Division  of  Gastroenterology,  Department  of  Internal  Medicine,  Eulji  University  College  of 
Medicine,  Eulji  University  Hospital,  1306  Dunsan-dong,  Seo-gu,  Daejeon  302-799,  Korea  Tel  :  82-42-611-3051, 
Fax  :  82-42-259-1111,  E-mail  :  jahuh@korea.com
INTRODUCTION
Primary  carcinoma  of  the  extrahepatic  bile  duct  is  a  rare 
tumor  that  represents  less  than  1.0%  of  all  malignant  neoplasms 
and  less  than  3.0%  of  all  the  tumors  of  the  gastrointestinal 
system
1).  Most  malignant  tumors  generated  in  the  biliary  tract 
are  adenocarcinomas,  and  adenosquamous  carcinoma  is  rare 
(3.0～4.7%).  Adenosquamous  carcinoma  consists  of  two 
malignant  components:  one  is  glandular  and  the  other 
squamous
2, 3).
In  one  previous  report  on  patients  with  extrahepatic 
adenosquamous  carcinoma  of  the  biliary  tract,  patients  were 
treated  with  surgical  resection.  the  overall  1-year,  3-year  and 
5-year  survival  rates  were  57%,  26%  and  16%,  respectively, 
and  the  median  survival  was  13  months
2).  When  used  for  the 
management  of  advanced  cholangiocarcinoma,  adjuvant 
external  beam  radiotherapy  (EBRT)  followed  by  surgical 
resection  with  or  without  intraluminal  radiotherapy  (ILRT)  is 
feasible,  but  the  effect  of  radio-therapy  alone  has  not  been 
established
4).
In  Korea,  adenosquamous  carcinoma  of  the  papilla  of  Vater 
and  the  liver  has  been  reported,  but  there  have  been  no 
previous  reports  on  adenosquamous  carcinoma  of  Klatskin's 
tumor
5, 6).  We  report  here  on  a  case  of  a  patient  with 
adenosquamous  carcinoma  of  Klatskin's  tumor,  and  this  was 
confirmed  by  endoscopic  biopsy.  The  patient  was  palliatively 
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Figure  1.  The  abdominal  computed  tomography  shows  both 
intrahepatic  duct  dilatation  and  an  enhanced  wall  thickening 
(arrow)  of  the  intrahepatic  duct  confluent  portion. 
Figure  2,  3.  The  magnetic  resonance  cholangiopancreatography 
shows  luminal  stenosis  of  both  the  intrahepatic  duct  confluent 
portion  and  the  common  hepatic  duct,  and  dilatation  of  both 
intrahepatic  ducts. 
CASE REPORT 
An  83-yr-old  man  was  admitted  to  Eulji  University  Hospital 
because  of  jaundice  he  had  experienced  for  the  past  4  days, 
and  this  was  preceded  by  chills  and  myalgia  for  the  previous 
week.  Ten  years  earlier,  he  had  undergone  percutaneous 
coronary  intervention  due  to  angina.  Six  months  previously,  he 
was  operated  on  for  laparascopic  cholecystectomy  due  to  acute 
acalculous  cholecystitis  with  empyema. 
On  admission,  his  blood  pressure  was  100/60  mmHg,  the 
heart  rate  was  66/min,  the  respiration  rate  was  20/min  and  the 
body  temperature  was  36.5℃.  He  looked  acutely  ill  and  showed 
an  alert  mentality.  His  sclera  was  icteric  and  he  complained  of 
abdominal  pain.  On  physical  examination,  there  was  no 
abdominal  tenderness,  rebound  tenderness  or  guarding  of  the 
abdomen.  There  was  no  palpable  mass  or  hepatomegaly  on  the 
abdominal  exam.  On  the  biochemical  analysis,  the  complete  blood 
count  was  as  follows:  the  white  blood  cell  count  was  9,740/μL,  the 
hemoglobin  level  was  13.8  g/dL  and  the  platelet  count  was 
225,000/μL.  The  laboratory  data  included  the  following:  total  serum 
bilirubin:  11.5  mg/dL,  serum  glutamic  oxaloacetic  transaminase: 
276  IU/L,  serum  glutamic  pyruvic  transaminase:  299  IU/L, 
alkaline  phosphatase:  487  IU/L,  serum  gamma  guanosine 
triphosphate:  640  IU/L,  amylase:  64  U/L,  lipase:  61  IU/L, 
alpha-fetoprotein:  5.1  ng/mL,  carcinoembrionic  antigen:  1.59 
ng/mL  and  carbohydrate  antigen  19-9:  120.62  U/mL. 
The  abdominal  computed  tomography  (CT)  revealed 
enhanced  wall  thickening  of  the  intrahepatic  duct  (IHD),  the 
confluent  portion  and  the  common  hepatic  duct  (CHD),  and  this 
was  all  compatible  with  Klatskin's  tumor.  The  CT  also  revealed 
enlarged  lymphadenopathy  of  the  portahepatis  (Figure  1). 
The  magnetic  resonance  cholangiopancreatography  (MRCP) 
revealed  luminal  stenosis  of  both  the  IHD  confluent  portion  and 
the  CHD,  and  dilatation  of  both  IHDs.  This  was  again 
compatible  with  Klatskin's  tumor,  Bismuth  type  IIIa  (Figure  2,  3). 
Considering  his  old  age,  palliative  external  radiotherapy  and 
intraluminal  brachytherapy  were  planned.  After  percutaneous 
transhepatic  biliary  drainage  (PTBD)  for  achieving  bile  drainage, 
biopsy  was  performed  via  percutaneous  transhepatic  cholangio-
scopy  (PTCS).  An  endobiliary  Y-type  stent  was  inserted  via  the 
Figure  2
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Figure 4. The endobiliary Y-type stent is inserted via percutaneous 
transhepatic  biliary  drainage  of  the  left  intrahepatic  duct. 
Figure  7.  The  light  microscope  findings  show  squamous  cell 
carcinoma,  including  keratin  (arrow)  and  intercelluar  bridges 
(arrowhead)  that  are  seen  in  the  tumor  tissue  (HE  stain,  original 
magnification  ×40). 
Figure  6.  The  light  microscope  findings  show  papillary  structure 
(arrowhead)  and  proliferation  of  nests  of  adenocarcinoma  cells 
(arrow)  (HE  stain,  original  magnification  ×40). 
Figure  5.  The  percutaneous  transhepatic  cholangioscopy  shows 
an  ingrowing  mass  in  the  perihilar  area. 
PTBD  of  the  left  IHD  (Figure  4,  5).
The  histopathologic  findings  showed  adenosquamous 
carcinoma  that  was  a  mix  of  adenocarcinoma  and  squamous 
cell  carcinoma  (Figure  6,  7). 
External  radiotherapy  (22  cycles,  total  dose:  3,960  cGy)  and 
intraluminal  brachytherapy  (2  cycles,  total  dose:  2,000  cGy)  were 
performed  through  an  endobiliary  Y-type  stent. 
PTCS  was  performed  one  month  after  the  radiotherapy.  This 
revealed  a  dilated  internal  lumen  by  the  endobiliary  Y-type  stent 
and  superficial  necrotized  yellowish  tissue  on  the  tumor  (Figure  8). 
During  the  monthly  follow-up  nine  months  after  the 
radiotherapy,  the  abdominal  CT  revealed  biliary  obstruction  and 
progressive  hepatic  metastasis.  PTBD  was  performed  and 
conservative  management  was  being  planned. 
DISCUSSION 
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Figure  8.  The  percutaneous  transhepatic  cholangioscopy  shows  a 
dilated  internal  lumen  via  the  endobiliary  Y-type  stent,  and 
superficial  necrotized  yellowish  tissue.
finding,  representing  less  than  5%  of  all  biliary  tumors.  Its  clinical 
characteristics,  pathogenesis  and  the  effect  of  radiotherapy 
without  surgical  resection  are  unknown
1).
Several  theories  have  explained  that  adenosquamous 
carcinoma  is  a  mix  of  adenocarcinoma  and  squamous  cell 
carcinoma,  and  this  is  a  malignant  epithelial  tumor  that's  derived 
from  initially  benign  metaplasia  as  a  result  of  some  chronic 
inflammatory  process.  Further,  squamous  cell  carcinoma  in 
these  unusual  sites  is  more  likely  to  be  due  to  squamous 
metaplasia  of  a  tumor  itself  rather  than  being  due  to  malignant 
transformation  of  previously  benign  metaplastic  epithelium
1). 
Histologic  alteration  from  adenocarcinoma  to  squamous  cell 
carcinoma  shows  that  adeno-squamous  carcinoma  might  be  a 
transitional  form  from  adenocarcinoma  to  squamous  cell 
carcinoma.  In  addition,  some  of  the  primary  hepatic  squamous 
cell  carcinomas  might  originate  from  adenocarcinomas,  and  this 
supports  the  theory  of  an  origin  from  adenocarcinoma
7, 8). 
Although  adenosquamous  carcinoma  of  the  common  bile 
duct  has  a  different  etiology  and  biologic  features  compared 
with  adenocarcinoma,  the  patients  with  adenosquamous 
carcinoma  are  treated  in  the  same  manner  as  that  for  patients 
with  adenocarcinoma.  Adenosquamous  carcinomas  are 
uncommon  tumors  with  a  poor  prognosis,  even  after  surgical 
resection.  The  median  survival  is  only  thirteen  months  and  no 
optimal  postoperative  adjuvant  therapy  has  been  established. 
The  outcomes  related  to  various  therapeutic  interventions  are 
not  well  defined
2).  In  one  previous  study  on  treating  patients  with 
inoperable  carcinoma  of  the  extrahepatic  bile  ducts,  group  1 
underwent  EBRT  alone  and  group  2  was  treated  with  EBRT  in 
combination  with  high-dose-rate  ILBT;  the  results  were  then 
compared.  No  statistically  significant  difference  was  found  in  the 
recurrence  rates  between  those  who  did  and  did  not  receive 
ILBT  (53%  for  group  1  vs.  36%  for  group  2;  p>0.05).  However, 
a  prolongation  of  the  median  time  to  tumor  recurrence  was 
observed  for  the  group  2  patients  (5  months  for  group  1  vs.  9 
months  for  group  2;  p=0.06)
9).  On  the  other  hand,  reports  exist 
that  performing  brachytherapy  boost  was  not  superior  to 
treatment  with  external  beam  irradiation  alone
10).  In  another 
study,  there  did  not  seem  to  be  any  difference  in  survival  or 
complications  between  the  low-  and  high-dose  rate 
brachytherapy
11).  Moreover,  high  radiation  doses  could  be 
dangerous  and  detrimental  to  the  prognosis
10).
Takamura  et  al.  reported  that  combined-modality  therapy, 
including  external  beam  radiotherapy,  intraluminal  irradiation  and 
biliary  stenting  for  extrahepatic  bile  duct  carcinoma  provided 
reasonable  local  control  and  improved  the  quality  of  life  for  the 
patients  with  extrahepatic  bile  duct  carcinoma.  The  median 
survival  was  twelve  months,  with  1-,  3-  and  5-year  actuarial 
survival  rates  of  50%,  10%  and  4%,  respectively
12).
Therefore,  the  outcomes  and  survival  rate  related  to 
radiotherapy  have  not  been  established  for  cases  of  inoperable 
extrahepatic  bile  duct  carcinoma  with  obstructive  jaundice.  Yet  it 
has  been  recently  reported  that  ILBT  with  metallic  stenting 
improves  the  quality  of  life  of  extrahepatic  bile  duct  carcinoma 
patients  with  obstructive  jaundice. 
The  reported  mean  time  of  stent  patency  was  421  days  in 
the  group  of  patient  with  proximal  malignant  biliary  stricture  and 
mean  time  of  stent  patency  was  168  days  for  the  group  of 
patients  with  distal  stricture  that  was  impossible  to  operate  on  or 
the  patients  refused  an  operation
13).  So,  we  expected  the  period 
of  stent  patency  to  be  more  than  six  months  for  our  case  of 
adenosquamous  carcinoma.  We  performed  combined  modality 
therapy  of  EBRT,  ILRT  and  stenting.  He  lived  a  normal  life  until 
he  experienced  biliary  obstruction.  Nine  months  after  the 
therapy,  the  abdominal  CT  and  laboratory  findings  showed 
recurred  biliary  obstruction. 
All  the  reported  cases  of  adenosquamous  carcinomas  have 
been  diagnosed  by  surgical  resection.  Any  inoperable  cases  that 
were  diagnosed  by  endoscopic  biopsy  have  not  yet  been  reported 
on  because  endoscopic  biopsy  is  not  generally  performed  before 
a  treatment  decision.  Thus,  the  response  to  radiotherapy,  including 
brachytherapy,  and  the  patency  rate  of  stents  in  inoperable 
adenosquamous  carcinoma  have  not  been  reported.
In  the  future,  a  reasonable  management  plan  for  adeno-
squamous  carcinoma  will  be  established  if  a  sufficiently  large 
number  of  cases  of  inoperable  adeno-squamous  carcinomas 
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